CoChat

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

The burden of illness in Lennox–Gastaut syndrome: a systematic literature review

Open access
Strzelczyk, Adam, Zuberi, Sameer M., Striano, Pasquale, Rosenow, Felix, Schubert-Bast, Susanne · 2023 · Orphanet Journal of Rare Diseases

Abstract

Background: Lennox–Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant epilepsy with multiple seizure types starting in childhood, a typical slow spike-wave pattern on electroencephalogram, and cognitive dysfunction. Methods: We performed a systematic literature review according to the PRISMA guidelines to identify, synthesize and appraise the burden of illness in LGS (including “probable” LGS). Studies were identified by searching MEDLINE, Embase and APA PsychInfo, Cochrane’s database of systematic reviews, and Epistemonikos. The outcomes were epidemiology (incidence, prevalence or mortality), direct and indirect costs, healthcare resource utilization, and patient and caregiver health-related quality of life (HRQoL). Results: The search identified 22 publications evaluating the epidemiology (n = 10), direct costs and resource (n = 10) and/or HRQoL (n = 5). No studies reporting on indirect costs were identified. With no specific ICD code for LGS in many regions, several studies had to rely upon indirect methods to identify their patient populations (e.g., algorithms to search insurance claims databases to identify “probable” LGS). There was heterogeneity between studies in how LGS was defined, the size of the populations, ages of the patients and length of the follow-up period. The prevalence varied from 4.2 to 60.8 per 100,000 people across studies for probable LGS and 2.9–28 per 100,000 for a confirmed/narrow definition of LGS. LGS was associated with high mortality rates compared to the general population and epilepsy population. Healthcare resource utilization and direct costs were substantial across all studies. Mean annual direct costs per person varied from $24,048 to $80,545 across studies, and home-based care and inpatient care were significant cost drivers. Studies showed that the HRQoL of patients and caregivers was adversely affected, although only a few studies were identified. In addition, studies suggested that seizure events were associated with higher costs and worse HRQoL. The risk of bias was low or moderate in most studies. Conclusions: LGS is associated with a significant burden of illness featuring resistant seizures associated with higher costs and worse HRQoL. More research is needed, especially in evaluating indirect costs and caregiver burden, where there is a notable lack of studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13023-023-02626-4

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Timeline to show A the history of the characterization and treatment of LGS B the triad of symptoms characteristic of LGS and the clinical implications of the characterization of the syndrome. From: Lennox et al (1950) [1], Gastraut et al (1966) [2], Niedermeyer (1969) [90], Beaumanoir (1985) [91], ILAE 1989 [92], Engel (2001) [93], Arzimanoglou et al (2009) [3], Scheffer (2017) [94], World Health Organization (ICD-11) (2022) [64]. CLB, clobazam; CBD, cannabidiol; EEG, electroencephalogram; FFA, fenfluramine; FLB, felbamate; ILAE, International League Against Epilepsy; LGS, Lennox–Gastaut syndrome; LTG, lamotrigine; RUF, rufinamide; TPM, topiramate
Fig 1 Timeline to show A the history of the characterization and treatment of LGS B the triad of symptoms characteristic of LGS and the clinical implications of the characterization of the syndrome. From: Lennox et al (1950) [1], Gastraut et al (1966) [2], Niedermeyer (1969) [90], Beaumanoir (1985) [91], ILAE 1989 [92], Engel (2001) [93], Arzimanoglou et al (2009) [3], Scheffer (2017) [94], World Health Organization (ICD-11) (2022) [64]. CLB, clobazam; CBD, cannabidiol; EEG, electroencephalogram; FFA, fenfluramine; FLB, felbamate; ILAE, International League Against Epilepsy; LGS, Lennox–Gastaut syndrome; LTG, lamotrigine; RUF, rufinamide; TPM, topiramateCC BY · PubMed Central
Fig 2 PRISMA flow diagram. Adapted from Page et al (2021) [95]
Fig 2 PRISMA flow diagram. Adapted from Page et al (2021) [95]CC BY · PubMed Central
Fig 3 A Total direct costs in LGS patients (blue) versus control patients (grey), patients with other epilepsies (lilac), and in LGS patients with seizure events vs without seizure events and LGS patients in years where patients were prescribed with rescue medication vs years where patients were not prescribed rescue medication (blue) B resource utilization and costs in LGS patients vs controls; C resource utilization and costs in LGS patients with seizure events vs without seizure events. Adapted from: Reaven et al (2018) [54], Piña-Garza et al (2017) [46], Stockl et al (2019) [55], Hollenack et al (2019) [52], Reaven et al (2019) [53] and Strzelczyk et al (2021) [47] .* Costs were converted from Euros to US dollars on 21st June 2022 (exchange rate 1.00 Euro =1.06 US Dollars [xe.com]). ASM, anti-seizure medication; DS, Dravet syndrome; ED, emergency department; LGS, Lennox–Gastaut syndrome; PPPY, per person per year; OP, outpatient; TSC, tuberous sclerosis complex
Fig 3 A Total direct costs in LGS patients (blue) versus control patients (grey), patients with other epilepsies (lilac), and in LGS patients with seizure events vs without seizure events and LGS patients in years where patients were prescribed with rescue medication vs years where patients were not prescribed rescue medication (blue) B resource utilization and costs in LGS patients vs controls; C resource utilization and costs in LGS patients with seizure events vs without seizure events. Adapted from: Reaven et al (2018) [54], Piña-Garza et al (2017) [46], Stockl et al (2019) [55], Hollenack et al (2019) [52], Reaven et al (2019) [53] and Strzelczyk et al (2021) [47] .* Costs were converted from Euros to US dollars on 21st June 2022 (exchange rate 1.00 Euro =1.06 US Dollars [xe.com]). ASM, anti-seizure medication; DS, Dravet syndrome; ED, emergency department; LGS, Lennox–Gastaut syndrome; PPPY, per person per year; OP, outpatient; TSC, tuberous sclerosis complexCC BY · PubMed Central
Fig 4 A Cost drivers according to inpatient and emergency department admissions (red), outpatient visits (orange), home health (home nursing and physiotherapy; blue), equipment (yellow) and medication (green) costs (where reported) B Patient and caregiver HRQoL according to number of drop seizures per month and number of seizure-free days in the UK and France. Mean health state utility scores for a hypothetical patient with LGS and a hypothetical caregiver of a patient with LGS. A Adapted from: Strzelczyk et al (2021) [47] and Reaven et al (2018) [54]. Home health= home-based nursing, personal care, and residential habilitation services. B Adapted from Auvin et al (2021) [61]. ASM, anti-seizure medication; ED, emergency department; HRQoL, health-related quality of life; OP, outpatient
Fig 4 A Cost drivers according to inpatient and emergency department admissions (red), outpatient visits (orange), home health (home nursing and physiotherapy; blue), equipment (yellow) and medication (green) costs (where reported) B Patient and caregiver HRQoL according to number of drop seizures per month and number of seizure-free days in the UK and France. Mean health state utility scores for a hypothetical patient with LGS and a hypothetical caregiver of a patient with LGS. A Adapted from: Strzelczyk et al (2021) [47] and Reaven et al (2018) [54]. Home health= home-based nursing, personal care, and residential habilitation services. B Adapted from Auvin et al (2021) [61]. ASM, anti-seizure medication; ED, emergency department; HRQoL, health-related quality of life; OP, outpatientCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Research works printed but not linked: 4

  1. Covidence. Systematic review management platform [Available from: https://www.covidence.org/]
  2. Hollenack K, Story T, Acs A, et al. Prevalence of probable dravet syndrome, Lennox–Gastaut syndrome, and other refractory epilepsies in commercial and medicaid populations in the United States. J Manag Care Spec Pharm. 2019;25(3-A SUPPL):S58.
  3. Stockl K, Funk S, Reaven N, et al. Inpatient hospitalizations and readmissions among patients with probable Lennox–Gastaut syndrome, dravet syndrome, tuberous sclerosis complex, and other refractory epilepsies. J Manag Care Spec Pharm. 2019;25(10-A SUPPL):S57–8.
  4. Umeno J. A survey on the utilization status of social welfare services for pediatric patients with epilepsy. [Japanese]. No To Hattatsu. 2019;51(4):23–49.

Cited by

See all 68

Metadata

Authors
Strzelczyk, A., Zuberi, S. M., Striano, P., Rosenow, F., & Schubert-Bast, S.
Affiliations
  • Goethe University Frankfurt (DE)
  • Royal Hospital for Children (GB)
  • Istituto Giannina Gaslini (IT)
Corresponding author
Strzelczyk, Adam
Venue
Orphanet Journal of Rare Diseases
Published
2023-03-01
Volume
18
Issue
1
Pages
42-42
ISSN
1750-1172 (ISSN-L)
OpenAlex
W4322733387
Cited by
68
References
87
Citations by year
2026: 18 · 2025: 26 · 2024: 20 · 2023: 4
FWCI
3.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
Funders
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
Lennox-Gastaut syndrome, disease burden, drug-resistant epilepsy, developmental and epileptic encephalopathy, prevalence, incidence, mortality, health care costs, healthcare resource utilization, health-related quality of life, caregiver burden, indirect costs
MeSH terms
Algorithms, Humans, Quality of Life, Seizures, Cost of Illness, Lennox Gastaut Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The burden of illness in Lennox–Gastaut syndrome: a systematic literature review. https://app.cochat.ai/papers/10.1186/s13023-023-02626-4
The paper
Strzelczyk, A., Zuberi, S. M., Striano, P., Rosenow, F., & Schubert-Bast, S. (2023). The burden of illness in Lennox–Gastaut syndrome: a systematic literature review. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-023-02626-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.